BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12001045)

  • 21. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Wessels MR; Paoletti LC; Pinel J; Kasper DL
    J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial of conjugated group B streptococcal type Ia vaccine in a rabbit model of ascending infection.
    Davies JK; Paoletti LC; McDuffie RS; Madoff LC; Lee S; Eskens J; Gibbs RS
    Am J Obstet Gynecol; 1999 Oct; 181(4):803-8. PubMed ID: 10521733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.
    Hillier SL; Ferrieri P; Edwards MS; Ewell M; Ferris D; Fine P; Carey V; Meyn L; Hoagland D; Kasper DL; Paoletti LC; Hill H; Baker CJ
    Clin Infect Dis; 2019 May; 68(12):2079-2086. PubMed ID: 30281066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppression and modulation of cellular and humoral immune responses to Haemophilus influenzae type B (Hib) conjugate vaccine in hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: a study in a rat model.
    Mawas F; Newman G; Burns S; Corbel MJ
    J Infect Dis; 2005 Jan; 191(1):58-64. PubMed ID: 15593004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isotype composition of antibodies to streptococcus group B type III polysaccharide and to tetanus toxoid in maternal, cord blood sera and in breast milk.
    Lagergård T; Thiringer K; Wassén L; Schneerson R; Trollfors B
    Eur J Pediatr; 1992 Feb; 151(2):98-102. PubMed ID: 1537371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults.
    Kotloff KL; Fattom A; Basham L; Hawwari A; Harkonen S; Edelman R
    Vaccine; 1996 Apr; 14(5):446-50. PubMed ID: 8735558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Protective Value of Maternal Group B Streptococcus Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera.
    Fabbrini M; Rigat F; Rinaudo CD; Passalaqua I; Khacheh S; Creti R; Baldassarri L; Carboni F; Anderloni G; Rosini R; Maione D; Grandi G; Telford JL; Margarit I
    Clin Infect Dis; 2016 Sep; 63(6):746-753. PubMed ID: 27402816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice.
    Paoletti LC; Pinel J; Rodewald AK; Kasper DL
    J Infect Dis; 1997 May; 175(5):1237-9. PubMed ID: 9129094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine.
    Marques MB; Kasper DL; Shroff A; Michon F; Jennings HJ; Wessels MR
    Infect Immun; 1994 May; 62(5):1593-9. PubMed ID: 8168919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies to capsular polysaccharides of group B Streptococcus in pregnant Canadian women: relationship to colonization status and infection in the neonate.
    Davies HD; Adair C; McGeer A; Ma D; Robertson S; Mucenski M; Kowalsky L; Tyrell G; Baker CJ
    J Infect Dis; 2001 Aug; 184(3):285-91. PubMed ID: 11443553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent.
    Bhushan R; Anthony BF; Frasch CE
    Infect Immun; 1998 Dec; 66(12):5848-53. PubMed ID: 9826364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization with meningococcal polysaccharide-tetanus toxoid conjugate induces polysaccharide-reactive T cells in mice.
    Muthukkumar S; Stein KE
    Vaccine; 2004 Mar; 22(9-10):1290-9. PubMed ID: 15003659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons.
    Paoletti LC; Kennedy RC; Chanh TC; Kasper DL
    Infect Immun; 1996 Feb; 64(2):677-9. PubMed ID: 8550227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective levels of human immunoglobulin G antibody to group B streptococcus type Ib.
    Boyer KM; Kendall LS; Papierniak CK; Klegerman ME; Gotoff SP
    Infect Immun; 1984 Sep; 45(3):618-24. PubMed ID: 6381309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study.
    Lin FY; Philips JB; Azimi PH; Weisman LE; Clark P; Rhoads GG; Regan J; Concepcion NF; Frasch CE; Troendle J; Brenner RA; Gray BM; Bhushan R; Fitzgerald G; Moyer P; Clemens JD
    J Infect Dis; 2001 Oct; 184(8):1022-8. PubMed ID: 11574917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
    Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
    Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate.
    Paoletti LC; Pinel J; Kennedy RC; Kasper DL
    J Infect Dis; 2000 Feb; 181(2):653-8. PubMed ID: 10669351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Designer vaccines to prevent infections due to group B Streptococcus.
    Kasper DL
    Proc Assoc Am Physicians; 1995 Oct; 107(3):369-73. PubMed ID: 8608425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surface-bound capsular polysaccharide of type Ia group B Streptococcus mediates C1 binding and activation of the classic complement pathway.
    Levy NJ; Kasper DL
    J Immunol; 1986 Jun; 136(11):4157-62. PubMed ID: 3517165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
    Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
    Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.